Clinical trial

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

NCT01202903

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Omalizumab Normalized identity: omalizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-09-01

PhasePHASE3

Conditions

Persistent Allergic Asthmaunresolved

Interventions

OmalizumabDRUG · verified · RxNorm: omalizumab

PlaceboDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Genentech, Inc.collaborator

Mapped research locations

BeijingChina6 ShanghaiChina4 ChangshaHunan, China3 ChongqingChina3 BeijingBeijing Municipality, China2 GuangzhouGuangdong, China2 WuhanHubei, China2 ShanghaiShanghai Municipality, China1 HangzhouZhejiang, China1 NanjingJiangsu, China1 ChengduSichuan, China1 GuangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01202903 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.